Cargando…
Iguratimod as an alternative induction therapy for refractory lupus nephritis: a preliminary investigational study
OBJECTIVES: Iguratimod, a novel immunomodulatory agent for rheumatoid arthritis, has been shown to be effective against murine lupus. The aim of this study was to make a preliminary evaluation of the efficacy and safety of iguratimod as salvage therapy in patients with refractory lupus nephritis (LN...
Autores principales: | Kang, Yuening, Yan, Qingran, Fu, Qiong, Wang, Ran, Dai, Min, Du, Fang, Dai, Qing, Ye, Ping, Wu, Chunmei, Lu, Liangjing, Bao, Chunde |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106733/ https://www.ncbi.nlm.nih.gov/pubmed/32228698 http://dx.doi.org/10.1186/s13075-020-02154-7 |
Ejemplares similares
-
Efficacy and safety of Iguratimod as an add-on therapy for refractory lupus nephritis: A preliminary investigational study
por: Yan, Qingran, et al.
Publicado: (2023) -
Prevention of Immune Nephritis by the Small Molecular Weight Immunomodulator Iguratimod in MRL/lpr Mice
por: Yan, Qingran, et al.
Publicado: (2014) -
Comparison of iguratimod and conventional cyclophosphamide with sequential azathioprine as treatment of active lupus nephritis: study protocol for a multi-center, randomized, controlled clinical trial (iGeLU study)
por: Yan, Qingran, et al.
Publicado: (2021) -
Iguratimod as an alternative therapy for systemic sclerosis and prevention of the occurrence of ischemic digital ulcer
por: Yan, Qingran, et al.
Publicado: (2023) -
Iguratimod attenuated fibrosis in systemic sclerosis via targeting early growth response 1 expression
por: Shen, Lichong, et al.
Publicado: (2023)